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Multiple donors are generally available for haploidentical hematopoietic stem cell transplantation. Here we
discuss the factors that should be considered when selecting donors for this type of transplantation according
to the currently available evidence. Donor-speciﬁc anti-HLA antibodies (DSAs) increase the risk of graft failure
and should be avoided whenever possible. Strategies to manage recipients with DSAs are discussed. One
should choose a full haplotype mismatch rather than a better-matched donor and maximize the dose of
infused hematopoietic cells. Donor age and sex are other important factors. Other factors, including predicted
natural killer cell alloreactivity and consideration of noninherited maternal alleles, are more controversial.
Larger studies are needed to further clarify the role of these factors for donor selection in haploidentical
hematopoietic stem cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.Haploidentical hematopoietic stem cell transplantation
(HSCT) is increasingly used for treatment of malignancies
and immune and hematologic diseases. This is largely related
to the development of posttransplantation cyclophospha-
mide, tacrolimus, andmycophenolate as an effective regimen
for prevention of graft-versus-host disease (GVHD) [1].
Recent studies have conﬁrmed the efﬁcacy of this approach,
with both nonmyeloablative and reduced-intensity ablative
conditioning [1-3]. There is increasing interest in this
regimenwith haploidentical transplants owing to a relatively
low rate of treatment-related mortality (TRM), low costs of
drugs and associated supportive care, and rapid availability
of donors when an urgent transplantation is needed.
Given that multiple mismatched related donors may be
available for transplantation, it is important to select the
donor most likely to produce a successful outcome. Parents,
children, and half-matched siblings are usually available for
a given patient. Here we discuss considerations for selection
of a haploidentical donor based on the current available
evidence.DONOR-SPECIFIC HLA ANTIBODIES
Haploidentical transplant recipients may have anti-HLA
antibodies against donor HLA antigens, induced by antigen
exposure during previous pregnancy or by blood product
transfusions. Some patients, particularly parous females, are
highly alloimmunized, with high titers of antibodies against
a broad range of HLA antigens. The presence of donor-
speciﬁc anti-HLA antibodies (DSAs), identiﬁed by single
antigen beads in a Luminex platform, are reportedly associ-
ated with graft failure with all forms of transplantation [4-7].
Whether this is a direct effect of the antibodies or anedgments on page 183.
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12.08.007associated Tcell response is unclear. DSAsmay possibly block
access of stem cells to the stem cell niche, decreasing avail-
able progenitor cells to engraft, and ultimately decrease the
stem cell dose necessary to achieve effective engraftment, as
suggested by some preclinical studies [8].
The presence of DSAs has been associated with an
increased risk of graft failure in HSCT, including in matched
unrelated donor (MUD) graft recipients, who are selected to
be matched for HLA-A, -B, -C, and -DRB1 but are usually
mismatched at the HLA-DP locus [4-7]. Engraftment is
favored by large cell doses of transplanted cells, possibly by
adsorption of the HLA antibodies. T celledepleted hap-
loidentical transplants appear to be especially predisposed to
graft failure in the presence of DSA, most likely due to the
lower cell dose and absence of T cells in the graft [4,5]. In our
recent analysis, DSAs were the single most important cause
of graft failure in MUD transplants [5], whereas in cord blood
transplants, the role of infused cell numbers in addition to
DSAs has been emphasized [6,7].
The levels of donor-speciﬁc anti-HLA antibodies may be
important, given that different antibody levels have been
associated with the risk of primary graft failure in different
types of HLA-mismatched transplants. T celledepleted hap-
loidentical transplant recipients with a DSA level of w1500
mean ﬂuorescence intensity (MFI) were found to have a high
rate of primary graft failure [3], as did MUD transplant
recipients with DSA against the HLA-DPB1 locus with levels
>2500 MFI [4]. In cord blood transplants, levels >1000 MFI
appeared to be deleterious to engraftment [6], whereas TCR-
haploidentical transplant recipients who failed to engraft
had DSA levels >5000 MFI [9].
Graft failure is not substantially increased if the recip-
ient has anti-HLA antibodies that do not react with donor
speciﬁcities [5]. One should select a donor with an HLA
type that is nonreactive with the recipient’s antibodies or
who has a low DSA titer, ideally <1000 MFI [3-7]. If
a patient has high DSA levels against all related donors, it
may be possible to identify an unrelated donorTransplantation.
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not targeted by the recipient’s anti-HLA antibodies. Many
recipients are broadly allosensitized and have high titers of
DSA against the mismatched HLA antigens in all potential
donors. How to best manage these patients to prevent graft
rejection is unclear. Selecting donors with the lowest
number of loci with DSA against and/or the lowest anti-
body levels is reasonable, as is treatment of allosensitized
recipients before transplantation to decrease antibody
levels using plasma exchange, rituximab, and i.v. gamma
globulin [3]. This strategy has been reported to be effective
for solid organ transplants, but its efﬁcacy in HSCT remains
to be conﬁrmed in clinical trials.
MAXIMIZING THE NUMBER OF STEM CELLS INFUSED BY
CHOOSING ABO-MATCHED DONORS
Numerous studies have demonstrated that infusion of
larger numbers of bone marrow cells improves survival after
HSCT [10-12]. Rocha et al. [10] reported that doses above the
mean (2.6  108 total nucleated cells [TNCs]/kg recipient
body weight) were associated with superior outcomes with
lower nonrelapse mortality (NRM) and disease relapse and
improved disease-free survival. Neutrophil recovery and
platelet recovery were faster, and the risk of GVHD was not
increased. Patients who received >3.8  108 TNCs/kg had
approximately 30% better disease-free survival compared
with those who received <1.6  108 TNCs/kg [9]. These
results were conﬁrmed in a subsequent study of patients
with various hematologic malignancies and different donor
types, which showed that these effects were more
pronounced in patients age>30 years with advanced disease
and with alternative donor sources [11].
Although it has not yet been shown speciﬁcally in hap-
loidentical bone marrow transplantation, cell dose is likely
an important determinant of treatment outcome. Hap-
loidentical HSCT has been associated with intense bidirec-
tional alloreactivity, including a higher predisposition
toward graft rejection compared with HLA-matched HSCT.
Engraftment is favored by infusion of large doses of CD34þ
cells; with T celledepleted haploidentical transplants,
“megadoses” of stem cells are needed to reliably achieve
engraftment [13,14]. The optimal dose for T cellereplete
transplants is unknown. Based on current knowledge, it is
desirable to administer the maximum dose of bone marrow
cells, with a goal of at least 3  108 TNCs/kg. T cellereplete
haploidentical transplants generally use bone marrow cells.
One approach to obtaining higher cell doses is to use gran-
ulocyte colony-stimulating factoremobilized peripheral
blood progenitor cells. This approach is under evaluation, but
there is a concern that this cell sourcemay be associatedwith
a higher rate of GVHD.
If maximizing the infused stem cell dose is important,
then the highest cell yields of bonemarrow harvests are from
young, larger donors. Transplants involving a major ABO
incompatibility requires mononuclear cell separation to
prevent a hemolytic reaction; this reduces the transplanted
cell dose and may predispose to graft failure [15,16]. If
possible, an ABO-compatible donor should be selected to
avoid manipulation of the graft that could reduce the cell
dose [16]. Our experience at M.D. Anderson Cancer Center in
recipients with minor and major ABO-incompatible donors
has shown average decreases of 11% and 34%, respectively, in
CD34þ cells/kg after processing and of 34% and 67% in TNC
cells. This suggests that if no ABO compatible donor is
available, then a donor with a minor ABO mismatch ispreferred over a donor with a major mismatch, because the
former is less likely to affect the number of cells infused.
Ensuring an adequate graft is the ﬁrst step in promoting
engraftment and successful transplantation.
CHOOSING A FULL HAPLOTYPE MISMATCH RATHER
THAN A BETTER-MATCHED DONOR
Historically, a progressive increase in TRM has been re-
ported with increasing genetic disparity in transplantation
from related or unrelated donors using conventional GVHD
prophylaxis [17-19]. The incidence of acute GVHD (aGVHD)
and TRM increased progressively with an increasing number
of mismatches [17]. In contrast to these ﬁndings, Kasamon
et al. [20] reported no increased incidence of aGVHD and
NRMwith full haplotype-mismatched transplantations using
posttransplantation cyclophosphamide, tacrolimus, and
mycophanolate immunosuppression. In their multivariate
analysis, patients with more than 3 mismatches appeared to
have better outcomes, based on a lower risk of relapse [20].
The presence of HLA-DRB1 mismatch in the graft-versus-
host direction and 2 or more HLA class I mismatches had
protective effects. Our results so far conﬁrm these ﬁndings
[3]. Moreover, our historical experience with single antigen-
mismatched related donors showed poor outcomes [21].
These results suggest that the use of a full haplotype-
mismatched donor is preferred to harness the maximum
graft-versus-tumor effect.DONOR AGE: YOUNGER DONORS ARE BETTER
Younger donors have a more cellular bone marrow, and
the immune system is subject to senescence with advancing
age. Donor age has been correlated with survival in a large
retrospective analysis of unrelated donor transplants facili-
tated by the National Marrow Donor Program [22]. Higher
incidence of grade III-IV aGVHD and chronic GVHD and lower
overall survival was correlated with older donor age. The
best outcomes were with donors age <30 years, and the
worst were with donors age >45 years. These differences
appeared more prominent in donors with mismatches [22].
These data clearly indicate a lower TRM with younger
donors, and although no data exist on an association
between donor age and outcomes of haploidentical HSCT, it
is probably safe to assume that a younger male donor is
preferred for transplantation. In female donors, age in
general is correlated with parity. Older multiparous women
may be the least preferred donors for male recipients, owing
to a higher incidence of GVHD and lower overall survival in
some studies, as discussed earlier. Taken together, our ﬁnd-
ings suggest that donor age and sex likely matter in trans-
plantation of any type and might be more important in
mismatched transplantation, owing to a potential greater
incidence of GVHD.
KILLER IMMUNOGLOBULIN-LIKE RECEPTOR MISMATCH/
NATURAL KILLER CELL ALLOREACTIVE DONOR
In a study of T celledepleted haploidentical trans-
plantation, Ruggeri et al. [23] found that natural killer (NK)
cell alloreactivity predicted by killer immunoglobulin-like
receptor (KIR) ligand donorerecipient mismatch was asso-
ciated with a decreased rate of relapse and improved
survival in patients with acute myelogenous leukemia, but
not in those with acute lymphoblastic leukemia. This
ﬁnding has remained controversial, with other investigators
not reporting improved outcomes with a KIR-mismatched
Table 1
Factors Considered in Donor Selection for Haploidentical HSCT
Factor Primary Aim Comment
DSA screen Decrease TRM Decreased risk of primary graft failure with HLA antibodies directed against donor HLA antigens
Young male donor Decrease TRM Greater cell dose yield
ABO match Decrease TRM Avoid an inadvertent decrease of infused cell dose associated with cell processing with a major
ABO-mismatched donor
Full haplotype-mismatched donor Decrease relapse Possibly greater antitumor effect associated with a higher number of HLA mismatches
NK cell alloreactive donor Decrease relapse Potential antitumor effect generated by alloreactive NK cells
NIMA-mismatched donor Decrease TRM Potential better tolerance if the mismatched haplotype is of maternal origin
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transplantation [24,25]. Huang et al. [25] reported an
increased incidence of GVHD and worse outcomes in
T cellereplete haploidentical transplantations with a KIRe
KIR ligand mismatch predicting NK cell alloreactivity; their
treatment regimen did not include posttransplantation
cyclophosphamide. Recently, Symons et al. [26] reported
a beneﬁcial effect of KIReKIR ligand mismatching in
T cellereplete haploidentical HSCT using posttransplantation
cyclophosphamide, tacrolimus, and mycophenolate as GVHD
prophylaxis. Outcomes were better in patients with an
inhibitory KIR haplotype, similar to the data reported by
Cooley et al. [27] in matched unrelated donor trans-
plantation. NK cells are important in the biology of hap-
loidentical transplants, and strategies for selection of donors
to optimize NK cellemediated antitumor effects should be
prospectively evaluated.Test for anti HLA antibodies 
recipient’s serum. 
DSA against potential donor
Choose full haplotype mismatch 
ABO-matched donor preferre
Male donor preferred 
Younger donor preferred 
 NIMA-mismatched donor pre
 NK-alloreactive donor prefe
NO 
Figure 1. Proposed algorithm for donor selection in haploidentical HSCT. DSA indic
NIMA, non-inherited maternal antigens; NK, natural killer.MALE VERSUS FEMALE DONOR, NONINHERITED
MATERNAL AND PATERNAL ALLELES
Whether donor sex or noninherited maternal or paternal
alleles affect transplantation outcomes is controversial.
Traditionally, sex-matched donors have been the preferred
source of stem cells for HSCT. This is due primarily to the
higher incidence of GVHD in male recipients of female donor
grafts, especially grafts from multiparous women, which is
attributed to reactivity against H-Y minor histocompatibility
antigens [28-32]. In studies of HSCT for malignancies, this
risk was counterbalanced by a lower relapse rate, indicating
that H-Y antigens also may be targets for the graft-versus-
malignancy effect. Randolf et al. [29] reported an increased
risk of grade II-IV aGVHD and a lower risk of relapse in male
recipients of female donor grafts, with lower overall survival
in this group. Several other studies have reported a greater
risk of aGVHD or chronic GVHD in recipients of sex-in  
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survival [30-32]. In T cellereplete haploidentical trans-
plantation, evidence from the Chinese group also suggests
improved transplantation outcomes in recipients of male
donor grafts [33]. In multivariate analysis, Huo et al. [33]
reported that a female donor, in addition to disease status,
was associated with worse outcomes related to higher TRM.
This same conclusion is supported by the Hopkins group in
the article by Kasamon et al. [20], who also reported that
a female donor for a male recipient was associated with
worse outcomes.
Immunologic tolerance between themother and the fetus
during pregnancy has been reported to produce life long
down-regulation of the immune responses and tolerance to
the antigens of maternal origin, with potential lower allo-
reactivity in both the graft-versus-host and host-versus-graft
(rejection) directions [34,35]. Consequently, the use of
donors with the mismatched (noninherited) haplotype of
maternal origin rather than paternal origin could inﬂuence
engraftment and transplantation outcomes.
This concept was initially demonstrated in solid organ
transplantation. The use of related donors with a mis-
matched haplotype of maternal origin (ie, noninherited
maternal antigen [NIMA]) compared with one of non-
inherited paternal antigen was associated with improved
graft survival in renal transplant recipients [36]. Patients
who received an NIMA-mismatched graft had similar graft
survival as those who received a graft from a full HLA-
identical donor [36].
Conﬂicting results have been reported in haploidentical
HSCT. Polchi et al. [37] suggested, based on a small series of
patients, that the use of maternal bone marrow stem cells
allows the use of noneT celledepleted haploidentical grafts
in children with advanced leukemia. A registry study from
Japan reported a lower TRM and superior survival of patients
with maternally derived rather than paternally derived bone
marrow or peripheral blood hematopoietic stem cells, more
noticeably in recipients of HLA-mismatched grafts [38].
However, maternal grafts were found to be associated with
higher risk of grade II-IV aGVHD and lower risk of relapse in
patients with hematologic malignancies [38]. Subsequent
work by van Rood et al. [39], in a Center for International
Blood and Marrow Transplant Research analysis, found
a lower incidence of aGVHD in noneT celledepleted hap-
loidentical transplant recipients mismatched for NIMA
compared with those mismatched for noninherited paternal
antigen, but similar TRM and overall survival in the 2 groups
of patients. Those authors also reported higher TRM and
worse overall survival in HSCT with parental donors
compared with HSCT with sibling donors [39].
Somewhat in disagreement with the foregoing results,
Stern et al. [40] reported better outcomes in T celledepleted
haploidentical HSCT with maternal donors compared with
paternal donors. The better survival was attributed to both
a reduced incidence of relapse and TRM, and the effect was
seen in both female and male recipients, suggesting that
alloreactivity against minor histocompatibility antigens
encoded by the Y chromosome did not play a major role. In
contrast to parent-to-child transplantation, donor sex played
no role in sibling transplantation in that study. The best
outcomes were obtained with an NK-alloreactive mother as
the donor [40].
Whether the presumably better tolerance associated with
using NIMA-mismatched sibling or maternal donors isassociated with better outcomes in T cellereplete hap-
loidentical HSCT remains unclear. The primary barrier to
answering this question is the relatively small number of
adult patients with a known source of mismatch haplotype,
given that parents are not usually HLA-typed.CONCLUSION
In conclusion, multiple related donors may be available
for haploidentical HSCT, and several factors identiﬁed to
affect transplantation outcomes should be considered in
donor selection (Table 1, Figure 1). Our data indicate that
avoidance of donor-speciﬁc anti-HLA antibodies, selection of
young donors, and transplantation of a large hematopoietic
cell dose improve outcome. The effects of KIR mismatch,
donor sex, and noninherited maternal and paternal alleles
are uncertain. Future studies involving larger numbers of
patients are needed to clarify the importance of these and
other immunogenic factors in selecting donors for hap-
loidentical HSCT.ACKNOWLEDGMENTS
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